Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Predicated upon a neuropharmacological conceptual model, there is now solid clinical evidence to support the efficacy of topiramate for the treatment of alcohol dependence. Topiramate treatment can be initiated whilst the alcohol-dependent individual is still drinking - just when crisis intervention is most likely to be needed by a patient with or without his or her family asking the health practitioner for assistance. Because topiramate can be paired with a brief intervention, there is now the exciting possibility of treating most alcohol- dependent individuals in office-based practice or generic treatment settings. Topiramate's additional effects on other impulsedyscontrol disorders make it a particularly interesting compound for the treatment of other comorbid drug or psychiatric disorders. Additionally, future studies should explore whether topiramate can be combined with other putative therapeutic agents to increase its efficacy. One notable clinical challenge in the development of topiramate as a pharmacotherapy to treat alcohol dependence is the determination of the smallest dose that can result in efficacy, thereby achieving the optimum balance between therapeutic benefit and adverse event profile. Animal data do provide support for topiramate's general anti-drinking effects but also indicate that its mechanisms of action might rely on several complex pharmacobehavioral changes. Additional preclinical studies are needed to elucidate more clearly the basic mechanistic processes that underlie topiramate's efficacy as a treatment for alcohol dependence. Preclinical information that topiramate may have differential effects based on genetic vulnerability opens up the possibility of future methods to optimize treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fagerström, K.-O. (1978) · Addictive Behaviors · doi:10.1016/0306-4603(78)90024-2 · Cited by 2,221 · cited 1×
“016) on the Fagerström test for nicotine dependence [97] and greater overall craving on the OCDS [86,87] (1.”
BackgroundSULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988 · cited 1×
“Alcohol-withdrawal scores assessed on the revised Clinical Institute Withdrawal Assessment for Alcohol scale [92] were exceedingly low and did not differ between the topiramate and placebo groups (mean difference = 0.”
MethodOral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Self-citationTopiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Self-citationMcElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484 · cited 1×
“Topiramate is being investigated as a potential treatment for a variety of other disorders, including: metabolic disorders such as diabetes mellitus and obesity; anxiety-related disorders such as post-traumatic stress disorder, and impulse dyscontrol-related disorders such as binge eating, pathological gambling, and s…”
BackgroundBray, G. A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., & Perry, B. H. (2003) · Obesity Research · doi:10.1038/oby.2003.102 · Cited by 344 · cited 1×
“Topiramate is being investigated as a potential treatment for a variety of other disorders, including: metabolic disorders such as diabetes mellitus and obesity; anxiety-related disorders such as post-traumatic stress disorder, and impulse dyscontrol-related disorders such as binge eating, pathological gambling, and s…”
BackgroundComparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Topiramate-Induced Nephrolithiasis
Kuo, R. L., Moran, M. E., Kim, D. H., Abrahams, H. M., White, M. D., & Lingeman, J. E. (2002) · Journal of Endourology · doi:10.1089/089277902753752188 · Cited by 76 · cited 1×
“Due to topiramate's tendency to increase the secretion of sodium and potassium ions, bicarbonate, and water and to cause acidosis, there is an increased likelihood of the formation of renal stones [24,53].”
BackgroundTopiramate selectively attenuates nicotine-induced increases in monoamine release
Schiffer, W. K., Gerasimov, M. R., Marsteller, D. A., Geiger, J., Barnett, C., Alexoff, D. L., & Dewey, S. L. (2001) · Synapse · doi:10.1002/syn.10000 · Cited by 69
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“Many of these problematic side effects are related to fast titration to high doses, and a slow titration to 300 mg/day over 6–8 weeks has been advocated (Johnson and Ait-Daoud, 2010).”
BackgroundTreatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“impairment and concentration disorder (Johnson, 2005, 2008; Johnson and Ait-Daoud, 2010; Batki et al., 2014).”
BackgroundNourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
“Bioavailability is 80% and is not affected by food [73].”
Background
Metadata
- Authors
- A. Johnson, B., & Ait-Daoud, N.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-06-01
- Volume
- 16
- Issue
- 19
- Pages
- 2103-2112
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2029327232
- Cited by
- 247
- References
- 9
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.